Making diversity and inclusion a core part of pharma’s DNA
We brought together a group of industry experts for our latest Media Lab workshop to discuss the process of making diversity and inclusion (D&I) a core part of pharma’s DNA. We covered how to build and nurture a diverse workforce, measure the progress and how to embed D&I in the DNA of companies.
In the past few years, a spotlight has been focused on ‘diversity and inclusion’ (D&I) across all industries. Audiences are not satisfied with ‘box ticking’ exercises or the hiring of a Chief D&I Officer – they want to see real, meaningful change, across all aspects, from the make-up of workforces and leadership teams to representation in clinical trials. The Media Lab at Page & Page and Partners has set out to discover whether the industry is committed to making D&I part of its DNA, or whether it is simply responding to public pressure to be more diverse.
This report summarises the key themes from a recent Media Lab roundtable discussion, where industry leaders explored diversity, inclusion and equality in pharma, from the importance of driving greater patient diversity and more inclusive workforces, to the vast challenges of achieving and measuring progress in this space.